AMPE News and Press, Ampio Pharmaceuticals Inc. From 01/04/21

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients PR Newswire ENGLEWOOD, Colo. , Jan. 4, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancem...

Strong SACCOVID clinical trial results suggest an approval is forthcoming. Graft versus Host Disease linkage to the most promising therapeutics. Merck business model resonating with investors. Small pool of therapeutic drug companies represents ideal acquisition targets. ...

These 3 Penny Stocks Were Trending On December 31 st ; Can That Continue? As New Year’s Eve comes and goes, a new year for penny stocks is upon us. In 2021, there are several factors that could change the trajectory of certain stocks. As investors, we always have to think...

Gainers: Hoth Therapeutics (HOTH) +49%. Bionano Genomics (BNGO) +38%. Clearside Biomedical (CLSD) +17%. Regional Health Properties (RHE) +14%. Ampio Pharmaceuticals (AMPE) +13%.Losers: Histogen (HSTO) -26%. Novan (NOVN) -22%. ORIC Pharmaceuticals (ORIC) -14%. DermTech (DMTK) -12%. T...

Ashford (AINC) +75%.PEDEVCO (PED) +62%.SGOCO (SGOC) +49%.Ebang International Holdings (EBON) +33%.Red Lion Hotels RLH +31% on being acquired by Sonesta.Canaan (CAN) +30%.AirNet Technology (ANTE) +25%.Hudson Capital HUSN +24% as FreightHub posts stellar Q3 results.Hoth Ther...

Gainers: Bionano Genomics (BNGO) +82%, DermTech (DMTK) +25%, IMAC Holdings (IMAC) +20%, Gritstone Oncology (GRTS) +15%, Hepion Pharmaceuticals (HEPA) +12%.Losers: Regional Health Properties (RHE) -20%, Osmotica Pharmaceuticals (OSMT) -20%, Equ...

Shares of Ampio Pharmaceuticals (NYSEMKT: AMPE) were tanking by 18.6% as of 3:42 p.m. EST on Tuesday. The big drop came after the company announced that it had received feedback from the U.S. Food and Drug Administration (FDA) on proposed modifications to the special protocol assess...

Ampio Pharmaceuticals (AMPE) says it has received guidance from the FDA regarding the impact of COVID-19 on its Phase III clinical trial for osteoarthritis of the knee ("OAK").Conducted under a Special Protocol Assessment, the late-stage trial involved the intra-articular injection ...

Ampio Receives feedback from the FDA on Ampio's Proposed Modifications to the special protocol assessment for Ampion treatment of severe Osteoarthritis of the knee PR Newswire ENGLEWOOD, Colo. , Dec. 29, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE Amer...

Gainers: Avinger (AVGR) +71%, Neoleukin Therapeutics (NLTX) +33%, Ampio Pharmaceuticals (AMPE) +25%, Odonate Therapeutics (ODT) +14%, INmune Bio (INMB) +9%.Losers: Jaguar Health (JAGX) -29%, Ocugen (OCGN) -23%, Second Sight Medical Produc...